Next Article in Journal
Predicting outcome of treatment with radiotherapy in endocrine ophthalmopathy
Previous Article in Journal
Cerebral edema and its treatment
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Stents in interventional cardiology

Virgilijus Grinius
Ramūnas Navickas
Ramūnas Unikas
Institute of Cardiology, Clinic of Cardiology, Kaunas University of Medicine, Lithuania
Author to whom correspondence should be addressed.
Medicina 2007, 43(3), 183;
Submission received: 12 December 2006 / Accepted: 5 March 2007 / Published: 10 March 2007


Since the first percutaneous transluminal coronary angioplasty performed by A. Gruentzig in 1977, percutaneous coronary interventions have become the most important treatment modality for coronary heart disease. Coronary angioplasty carried a significant risk of coronary flow-limiting dissections and restenosis during the first six months following the procedure. Two main studies comparing percutaneous transluminal coronary angioplasty and coronary stenting (STRESS and BENESTENT) performed in 1994 showed a significant reduction in restenosis rate using stents. Thus, until now stents are the most widely used devices for coronary intervention despite two problems: subacute stent thrombosis (1–2%) and still high restenosis rate (5–40%). Subacute stent thrombosis occurs within the first month after stent placement and can be prevented using the double antiplatelet regimen with aspirin and clopidogrel. Some risk of subacute thrombosis remains beyond the first month when drug-eluting stents are used. This requires prolonged antiplatelet therapy. Drugeluting stents are the most significant innovation in interventional cardiology. They can reduce the incidence of restenosis in native stable coronary arteries to 3–5%. However, the long-term studies comparing bare-metal stents and drug-eluting stents did not show any significant differences in the rate of major adverse cardiac events (death, myocardial infarction), especially in patients with diabetes after the treatment of bifurcational lesions. According to proposed recommendations, drug-eluting stents should be used in small vessels, restenotic lesions, and in saphenous vein grafts. Despite some disadvantages, the results of coronary stenting using drugeluting stents continue to improve.
Keywords: stents; restenosis; drug-eluting stents; thrombosis stents; restenosis; drug-eluting stents; thrombosis

Share and Cite

MDPI and ACS Style

Grinius, V.; Navickas, R.; Unikas, R. Stents in interventional cardiology. Medicina 2007, 43, 183.

AMA Style

Grinius V, Navickas R, Unikas R. Stents in interventional cardiology. Medicina. 2007; 43(3):183.

Chicago/Turabian Style

Grinius, Virgilijus, Ramūnas Navickas, and Ramūnas Unikas. 2007. "Stents in interventional cardiology" Medicina 43, no. 3: 183.

Article Metrics

Back to TopTop